Observational Study of NovoNorm® in Subjects With Diabetes

NCT01498913 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5841

Last updated 2017-02-20

No results posted yet for this study

Summary

This study is conducted in Asia. The aim of this study is to review the safety and efficacy of Novonorm® (repaglinide) in post-marketing use.

Conditions

Interventions

DRUG

repaglinide

Prescription with NovoNorm® 0.5mg, 1mg or 2mg tablets according to product labelling in daily clinical practice at the discretion of the physician

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-08-30
Primary Completion
2005-03-25
Completion
2005-03-25

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01498913 on ClinicalTrials.gov